局部区域复发乳腺癌的再程放疗经验
本研究回顾1999至2019年单中心72例局部区域复发或第二原发乳腺癌接受再程乳腺/胸壁放疗的患者,中位随访22个月,3级不良事件发生率13%,2年局部区域无复发生存率74.6%、总生存率65.5%,在无肉眼病灶的根治性再程放疗患者中分别为93.1%和76.8%。
要点
- 再程放疗3级不良事件13%,其中急性皮肤毒性10%、晚期皮肤坏死3%。
- 全部患者2年局部区域无复发生存74.6%,总生存65.5%。
- 无肉眼病灶根治性再程放疗患者2年局部区域无复发生存93.1%、总生存76.8%。
核心结论
- 局部区域复发乳腺癌再程放疗可行,毒性可接受。
- 无肉眼病灶的根治性再程放疗患者疾病控制和生存前景良好。
研究设计与样本
- 1999至2019年单中心回顾性研究,纳入72例接受再程乳腺/胸壁放疗的乳腺癌患者。
- 不良事件采用CTCAE v5.0评估,生存分析采用Kaplan-Meier法。
主要发现
- 中位既往放疗剂量60 Gy(IQR 50-60.4 Gy),再程放疗剂量45 Gy(IQR 40-50 Gy),中位累积剂量103.54 Gy2(IQR 95.04-109.62 Gy2)。
- 中位随访22个月(IQR 10-43个月),3级不良事件13%(急性皮肤毒性10%,晚期皮肤坏死3%)。
- 两次放疗间隔和再程放疗野与任何时间3级毒性发生显著相关;质子治疗有剂量学优势但毒性无差异。
关键数值与推荐
- 全部患者2年局部区域无复发生存74.6%,总生存65.5%。
- 无肉眼病灶的根治性再程放疗患者2年局部区域无复发生存93.1%,总生存76.8%。
- 根治性 intent 患者2年无远处转移生存59.0%。
临床怎么用
- 再程放疗可用于局部区域复发乳腺癌,尤其对无肉眼病灶的根治性患者可考虑。
- 需关注两次放疗间隔和再程放疗野对3级毒性的影响。
- 质子治疗可作为剂量学优化选择,但未显示毒性差异。
局限性
- 单中心回顾性研究,样本量72例,中位随访22个月。
- 原文未报告对照组或前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Reirradiation poses a distinct therapeutic challenge owing to risks associated with exceeding normal tissue tolerances and possibly more therapeutically resistant disease biology. We report our experience with reirradiation for locoregional recurrent or second primary breast cancer. METHODS AND MATERIALS: Between 1999 and 2019, all patients with breast cancer treated with repeat breast/chest wall radiation therapy (RT) at our institution were identified. Adverse events were assessed using the Common Terminology Criteria for Adverse Events v5.0. Fisher exact, Mann-Whitney rank-sum, and unpaired t tests were used for statistical analysis. Freedom from locoregional recurrence and distant metastasis as well as overall survival were calculated using the Kaplan-Meier method. RESULTS: Seventy-two patients underwent reirradiation. Median prior RT dose, reirradiation dose, and cumulative dose were 60 Gy (interquartile range [IQR], 50-60.4 Gy), 45 Gy (IQR, 40-50 Gy), and 103.54 Gy2 (IQR, 95.04-109.62 Gy2), respectively. Median time between RT courses was 73 months (IQR, 29-129 months). Thirty-four patients (47%) had gross residual disease at time of reirradiation. Course intent was described as curative in 44 patients (61%) and palliative in 28 (39%). Fifty-two patients (72%) were treated with photons ± electrons and 20 (28%) with protons. With a median follow-up of 22 months (IQR, 10-43 months), grade 3 adverse events were experienced by 13% of patients (10% acute skin toxicity and 3% late skin necrosis). Time between RT courses and reirradiation fields was significantly associated with the development of grade 3 toxicity at any point. Proton therapy conferred a dosimetric advantage without difference in toxicity. At 2 years, locoregional recurrence-free survival was 74.6% and overall survival was 65.5% among all patients, and 93.1% and 76.8%, respectively, among curative intent patients treated without gross disease. Distant metastasis-free survival was 59.0% among all curative intent patients. CONCLUSIONS: Reirradiation for locoregional recurrent breast cancer is feasible with acceptable rates of toxicity. Disease control and survival are promising among curative intent reirradiation patients without gross disease.
引用
- Fattahi S, Ahmed SK, Park SS, et al. Reirradiation for Locoregional Recurrent Breast Cancer. Adv Radiat Oncol. 2020. PMID: 33506143. doi:10.1016/j.adro.2020.100640
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。